Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Omega Therapeutics, Inc. (OMGA : NSDQ)
 
 • Company Description   
Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 117

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.20 Daily Weekly Monthly
20 Day Moving Average: 81,632 shares
Shares Outstanding: 55.02 (millions)
Market Capitalization: $396.17 (millions)
Beta: 0.97
52 Week High: $11.98
52 Week Low: $2.05
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.67% -14.05%
12 Week 3.15% -4.25%
Year To Date 26.09% 14.70%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
20 ACORN PARK DRIVE
-
CAMBRIDGE,MA 02140
USA
ph: 617-949-4360
fax: -
estroynowski@omegatx.com http://www.omegatherapeutics.com
 
 • General Corporate Information   
Officers
Mahesh Karande - President; Chief Executive Officer and Director
Noubar B. Afeyan - Chairman of the Board of Directors
Joshua Reed - Chief Financial Officer
Rainer Boehm - Director
Luke M. Beshar - Director

Peer Information
Omega Therapeutics, Inc. (CORR.)
Omega Therapeutics, Inc. (RSPI)
Omega Therapeutics, Inc. (CGXP)
Omega Therapeutics, Inc. (BGEN)
Omega Therapeutics, Inc. (GTBP)
Omega Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 68217N105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/03/23
Share - Related Items
Shares Outstanding: 55.02
Most Recent Split Date: (:1)
Beta: 0.97
Market Capitalization: $396.17 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.05 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.22
Price/Cash Flow: -
Price / Sales: 170.61
EPS Growth
vs. Year Ago Period: -19.05%
vs. Previous Quarter: 21.87%
Sales Growth
vs. Year Ago Period: 92.54%
vs. Previous Quarter: -29.80%
ROE
03/31/23 - -82.93
12/31/22 - -71.03
09/30/22 - -55.11
ROA
03/31/23 - -64.81
12/31/22 - -56.55
09/30/22 - -45.58
Current Ratio
03/31/23 - 8.22
12/31/22 - 6.26
09/30/22 - 10.96
Quick Ratio
03/31/23 - 8.22
12/31/22 - 6.26
09/30/22 - 10.96
Operating Margin
03/31/23 - -4,643.24
12/31/22 - -4,951.83
09/30/22 - -6,252.80
Net Margin
03/31/23 - -4,643.24
12/31/22 - -4,951.83
09/30/22 - -6,252.80
Pre-Tax Margin
03/31/23 - -4,643.24
12/31/22 - -4,954.22
09/30/22 - -6,253.54
Book Value
03/31/23 - 2.24
12/31/22 - 2.21
09/30/22 - 2.79
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.11
12/31/22 - 0.16
09/30/22 - 0.15
Debt-to-Capital
03/31/23 - 10.29
12/31/22 - 13.55
09/30/22 - 12.96
 

Powered by Zacks Investment Research ©